000 01580 a2200493 4500
005 20250513050235.0
264 0 _c19950406
008 199504s 0 0 eng d
022 _a1043-1802
024 7 _a10.1021/bc00020a003
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aApelgren, L D
245 0 0 _aChemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs.
_h[electronic resource]
260 _bBioconjugate chemistry
_c
300 _a121-6 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdenocarcinoma
_xpathology
650 0 4 _aAnimals
650 0 4 _aAntibodies, Monoclonal
_xchemistry
650 0 4 _aCell Death
_xdrug effects
650 0 4 _aDrug Stability
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aImmunotoxins
_xadministration & dosage
650 0 4 _aMice
650 0 4 _aMice, Nude
650 0 4 _aMolecular Structure
650 0 4 _aNeoplasm Transplantation
650 0 4 _aOvarian Neoplasms
_xdrug therapy
650 0 4 _aRats
650 0 4 _aTumor Cells, Cultured
650 0 4 _aVinblastine
_xadministration & dosage
700 1 _aBailey, D L
700 1 _aBriggs, S L
700 1 _aBarton, R L
700 1 _aGuttman-Carlisle, D
700 1 _aKoppel, G A
700 1 _aNichols, C L
700 1 _aScott, W L
700 1 _aLindstrom, T D
700 1 _aBaker, A L
773 0 _tBioconjugate chemistry
_gvol. 4
_gno. 2
_gp. 121-6
856 4 0 _uhttps://doi.org/10.1021/bc00020a003
_zAvailable from publisher's website
999 _c7872981
_d7872981